Mass Spectrometry Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
|出版商||Mordor Intelligence Pvt Ltd||商品編碼||391377|
|出版日期||內容資訊||英文 125 Pages
|質譜分析的全球市場:成長，趨勢及預測(2017年∼2022年) Mass Spectrometry Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)|
|出版日期: 2021年05月13日||內容資訊: 英文 125 Pages||
The mass spectrometry market registered a value of USD 4,975 million in 2020, and it is expected to reach USD 7,780 million by 2026, with a CAGR of nearly 7.4% during the forecast period, 2021-2026. Certain factors that are driving the market growth include the increasing technological advancements, growing concerns over food safety, and rising R&D expenditure by the pharmaceutical industry and government research organizations.
Mass spectrometry is one of the powerful tools used for the analysis of chemical and biological entities. In addition, the high demand from the biotechnology and pharmaceutical industries due to COVID-19 is driving the market. In 2020, in India, researchers at the Delhi-based Institute of Genomics and Integrative Biology (IGIB) and the National Centre for Disease Control (NCDC) were able to detect novel coronavirus (COVID-19) with 95% sensitivity and 100% specificity with respect to RT-PCR using a mass spectrometer.
According to the Organization for Economic Co-operation and Development (OECD), in 2018, in Germany, approximately 3.13% of GDP was spent on research and development, which was an increase from 3.07% of GDP in 2017 and 2.94% of GDP in 2016, respectively. Increasing investments in research and development activities are expected to increase the demand for mass spectrometer in drug development, proteomics, and pharmaceuticals, thereby driving the market growth.
Furthermore, advancements in mass spectroscopy technology were able to increase the factors like rapid test results with high resolution. The discovery of new tools has the potential to stimulate the usage of mass spectroscopy across drug development, pharmaceuticals, food safety testing, proteomics, and other fields.
The demands of life sciences applications have led to the improvement of mass spectrometry technologies. The mass spectrometry MALDI-ToF is used as a clinical diagnostic platform utilizing a highly advanced method of protein pattern recognition to diagnose diseases. Hence, with the increasing technological advancements, the market is expected to grow over the forecast period.
The Triple Quadrupole (Tandem) Segment is Expected to Hold a Significant Market Share
As per the scope of this report, mass spectrometry (MS) is an analytical chemistry technique used to identify the amount and type of chemical species present in a sample. Currently, the tandem mass spectrometry devices are among the most in-demand. Liquid chromatography-mass spectrometry (LC-MS/MS)-based approaches are considered reagent-free. The high sensitivity and specificity of mass spectrometry can overcome many limitations associated with immunoassays, such as cross-reactivity and non-specific antibody binding.
There is a higher demand for triple quadrupole mass spectrometer because triple quadrupole mass spectrometer is considered one of the most high-end instruments, and moreover, many labs across the world are adopting this instrument.
For instance, according to a research article by Malin Kallsten et al., published in the Analytical and Bioanalytical Chemistry Journal 2019, there has been a trend in mass spectrometry-based characterization of antibody-drug conjugates (ADCs) toward the use of high-resolving mass spectrometry for many of these analyses. Quadrupole mass spectrometers represent a viable alternative for the characterization of antibody-drug conjugates (ADCs) in early-stage drug development.
As per the Patented Medicine Prices Review Board 2018 report, in 2018, total R&D spending by the pharmaceutical industry was around CAD 0.89 billion, which was an increase from CAD 0.87 billion in 2017. Thus, the increasing R&D spending on pharmaceuticals is expected to drive the demand for mass spectrometers in the near future.
Moreover, a UK biotech laboratory has used mass spectrometry for coronavirus testing. In April 2020, the UK diagnostics firm MAP Sciences announced the development of a rapid test for the COVID-19 virus. This technology deploys mass spectrometry to spot proteins that are unique to COVID-19 and is targeting to deliver test results within 30 minutes. These advancements are expected to fuel the growth of the studied market.
North America is Expected to Hold a Major Market Share Over the Forecast Period
The major factors driving the market growth in the North American region include the growing funding for research and government initiatives in the United States, widespread usage of mass spectrometry in the metabolomics and petroleum sectors, and the presence of key market players.
The US government spends a significant percentage of its GDP on R&D. According to a 2018 report published by the Organization for Economic Co-operation and Development (OECD), about 2.82% of the country's GDP was spent on R&D. In addition, in 2019, the research and development (R&D) expenditure of the US pharmaceutical industry was around USD 83 billion up from USD 79.6 billion in 2018 and USD 71.4 billion in 2017. Thus, increasing R&D activities increase the demand for mass spectrometers and drive the market growth.
Drug development is an expensive and lengthy process, and the failure rate is also high. Factors such as long time periods, high failure rates, and high costs are forcing researchers to look for newer technologies.
Additionally, mass spectroscopy is also being used in clinical laboratories to measure small sample volumes with improved confidence across an expanding range of healthcare applications, from toxicology to personalized medicine.
As per a September 2020 article published in Oxford Academics, in the United States, response to the COVID-19 pandemic has been hampered by inadequate testing resources. Therefore, technologies such as matrix-assisted laser desorption/ionization combined with mass spectrometry (MALDI-MS) are used to provide faster and cheaper diagnoses, which may drive their demand over the forecast period.
The mass spectrometry market is highly competitive. The leading players offer an expansive product portfolio for mass spectrometers and have a broad geographic presence. Companies like Agilent Technologies, Bruker Corporation, Danaher Corporation, Leco Corporation, Perkin Elmer Inc., Shimadzu Corporation, Thermo Fisher Scientific, and Waters Corporation, among others, hold a substantial share in the mass spectrometry market.